Expert consensus on the optimal management of BRAF V600E -mutant metastatic colorectal cancer in the Asia-Pacific region.

Autor: Piercey O; Peter MacCallum Cancer Centre, Melbourne, Victoria, Australia., Chantrill L; Illawarra Shoalhaven Local Health District, Illawarra, New South Wales, Australia.; Faculty of Science, Medicine and Health, University of Wollongong, Wollongong, New South Wales, Australia., Hsu HC; Division of Hematology Oncology, Chang Gung Memorial Hospital, New Taipei, Taiwan.; College of Medicine, Chang Gung University, Taoyuan, Taiwan., Ma B; State Key Laboratory of Translational Oncology, Sir YK Pao Centre for Cancer, Department of Clinical Oncology, Hong Kong Cancer Institute, The Chinese University of Hong Kong, Hong Kong SAR, China., Price T; The Queen Elizabeth Hospital, Adelaide, South Australia, Australia., Tan IB; Division of Medical Oncology, National Cancer Centre Singapore, Singapore, Singapore., Teng HW; Department of Oncology, Taipei Veterans General Hospital, Taipei, Taiwan., Tie J; Peter MacCallum Cancer Centre, Melbourne, Victoria, Australia.; Sir Peter MacCallum Department of Oncology, The University of Melbourne, Melbourne, Victoria, Australia., Desai J; Peter MacCallum Cancer Centre, Melbourne, Victoria, Australia.; Sir Peter MacCallum Department of Oncology, The University of Melbourne, Melbourne, Victoria, Australia.
Jazyk: angličtina
Zdroj: Asia-Pacific journal of clinical oncology [Asia Pac J Clin Oncol] 2024 Oct 25. Date of Electronic Publication: 2024 Oct 25.
DOI: 10.1111/ajco.14132
Abstrakt: The burden of colorectal cancer (CRC) is high in the Asia-Pacific region, and several countries in this region have among the highest and/or fastest growing rates of CRC in the world. A significant proportion of patients will present with or develop metastatic CRC (mCRC), and BRAF V600E -mutant mCRC represents a particularly aggressive phenotype that is less responsive to standard chemotherapies. In light of recent therapeutic advances, an Asia-Pacific expert consensus panel was convened to develop evidence-based recommendations for the diagnosis, treatment, and management of patients with BRAF V600E -mutant mCRC. The expert panel comprised nine medical oncologists from Australia, Hong Kong, Singapore, and Taiwan (the authors), who met to review current literature and develop eight consensus statements that describe the optimal management of BRAF V600E -mutant mCRC in the Asia-Pacific region. As agreed by the expert panel, the consensus statements recommend molecular testing at diagnosis to guide individualized treatment decisions, propose optimal treatment pathways according to microsatellite stability status, advocate for more frequent monitoring of BRAF V600E -mutant mCRC, and discuss local treatment strategies for oligometastatic disease. Together, these expert consensus statements are intended to optimize treatment and improve outcomes for patients with BRAF V600E -mutant mCRC in the Asia-Pacific region.
(© 2024 The Author(s). Asia‐Pacific Journal of Clinical Oncology published by John Wiley & Sons Australia, Ltd.)
Databáze: MEDLINE
Externí odkaz: